CA9 and cancer: The evidence for these molecules as reliable markers of hypoxia has been reviewed elsewhere (7,10–12) and the overexpression of HIF-1α, CA9, GLUT1 and VEGF in various malignant tumors has also been demonstrated (8–14,17–20).